From Nasdaq: 2025-04-02 07:40:00

AngioDynamics (ANGO) reported quarterly earnings of $0.03 per share, surpassing expectations and representing an earnings surprise of 123.08%. The company posted revenues of $72 million, exceeding estimates by 2%. The stock has gained 5.5% year-to-date. Analysts are now looking at the company’s earnings outlook to determine future performance.

Investors are advised to keep an eye on AngioDynamics’ earnings estimate revisions and industry outlook, as these factors can impact stock performance. The current consensus EPS estimate is -$0.09 for the next quarter and -$0.37 for the fiscal year. The company currently holds a Zacks Rank #3 (Hold) and is in the top 30% of Zacks-ranked industries.

Zacks Investment Research offers insights on whether to invest in AngioDynamics. For more stock recommendations and analysis, investors can access Zacks Investment Research’s free report on the 7 best stocks to buy for the next 30 days. The Zacks Rank system has outperformed the S&P 500 with an average gain of +24.08% per year.

To stay informed about the latest recommendations and analysis from Zacks Investment Research, investors can download the free report on the 7 best stocks for the next 30 days. This information can provide valuable insights for making investment decisions. Check out the free report for more details on AngioDynamics, Inc. and other top stock picks.



Read more at Nasdaq: AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates